PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar maniacdog (< 20) Submitted: 7/15/2011 3:57:40 PM : Outperform Start Price: $5.78 PDLI Score: +11.22

I bought 550 shares in real life today I hope I am right.

Report this Post Reply

Featured Broker Partners


Advertisement